GE’s Genomic Future
On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and drug firms such as Roche and Abbott Laboratories.
Medicine’s Big Bottleneck
If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.
Stem cell bill eyed as lure to biotech firms
A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.
What’s Really Banging Up Biovail?
The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics think something more may be going on
European biotech – surviving the storm
To endure a storm, a sailor must frequently tack and adjust the rigging and the analogy holds true for those at the helm of Europe�s biotechnology companies.
Pharma marketing’s changing skills set
As the pharmaceutical industry reacts to change there is a race to find high-calibre commercial executives, but what skills should these individuals possess?
Create Competition In Expanding Biotech Field
The biotech field is booming and managed care is scrambling to level the playing field by creating competition.
Bacteria Make More Electricity
Researchers from the University of Massachusetts at Amherst have identified a microorganism that is particularly good at converting sugars to electricity under natural conditions.
Geneticists hunt control patterns
The Human Epigenome Project will look for patterns in our ‘life code’ that are associated with gene regulation but are also implicated in causing disease.
Researchers at Epigenomics AG in Berlin and the Sanger Institute in Cambridge will take part in the five-year study.